Immunic Inc

NASDAQ:IMUX  
9.82
-0.63 (-6.03%)
Other Pre-Announcement

Immunic Inc Announces Enrollment Of The First Patient In Its Phase 1 Trial Of Imu-935 In Metastatic Castration-Resistant Prostate Cancer

Published: 12/09/2021 21:16 GMT
Immunic Inc (IMUX) - Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of Imu-935 in Metastatic Castration-resistant Prostate Cancer.
Immunic Inc - Re-iterates Its Prior Guidance That Data From Multiple Ascending Dose Part of Ongoing Phase 1 Trial of Imu-935 is Expected in Q4 of 2021.
Immunic Inc - Initial Clinical Data in Psoriasis Expected in Q2 of 2022,.
Immunic Inc - Regarding Vidofludimus Calcium (imu-838), Phase 2 Top-line Data in Ulcerative Colitis is Expected to Be Available in Q2 of 2022.